Abstract:Abstract Topoisomerase I (Top1) is an important target for developing novel anticancer agents. The discovery of natural product camptothecin (CPT) as a specific Top1 inhibitor and the development of synthetic CPT derivatives topotecan and irinotecan into clinical use represent a great achievement in antitumor drug discovery. However, clinically approved CPT derivatives have several major limitations such as chemical instability, drug resistance, and side effects. Thus, the discovery of novel Top1 inhibitors has recently emerged as a promising field to find better antitumor agents. Currently, identification of novel Top1 inhibitors is still largely dependent on the optimization of natural CPT and the screening of natural products. In recent years, a number of new CPT derivatives and natural products have been reported to be novel Top1 inhibitors. Several of them showed higher Top1 inhibitory activity, chemical stability, and antitumor activity, which had promising future for overcoming the limitations of CPT. This review will provide recent progress in novel Top1 inhibitors derived from natural products. In particular, we will focus on (1) new chemical scaffolds and structure–activity relationships; (2) their binding mode with Top1–DNA binary complex; (3) new natural product derivatives with improved pharmacological and pharmacodynamic profiles (eg, evodiamines, indolocarbazoles, lamellarins, wakayins, tsitsikammamines, berberines, and topopyrones).

Development of Indenoisoquinoline Derivatives as Novel Topoisomerase 1 Inhibitors

Developments of Indenoisoquinolines

New Strategies in the Discovery of Novel Non-Camptothecin Topoisomerase I Inhibitors

Synthesis, Cytotoxicity and Structure-Activity Relationship of Indolizinoquinolinedione Derivatives As DNA Topoisomerase IB Catalytic Inhibitors

Design, synthesis and biological evaluation of 3-substituted indenoisoquinoline derivatives as topoisomerase I inhibitors

Discovery of a Novel Series of Quinolone and Naphthyridine Derivatives As Potential Topoisomerase I Inhibitors by Scaffold Modification.

Discovery of Indolo[3,2- c]isoquinoline Derivatives as Novel Top1/2 Dual Inhibitors with Orally Efficacious Antitumor Activity and Low Toxicity

Synthesis and biological evaluations of novel indenoisoquinolines as topoisomerase I inhibitors.

Topoisomerase I Inhibitors Derived From Natural Products: Structure-Activity Relationships And Antitumor Potency

Research progress of topoisomeraseⅠ inhibitors as anticancer drugs

Synthesis and Biological Evaluation of 6-Substituted Indolizinoquinolinediones As Catalytic DNA Topoisomerase I Inhibitors.

Recent Advances in Non-camptothecin DNA Topoisomerase I Inhibitors as Anticancer Drugs

Synthesis and Biological Evaluation of Novel Indole-Pyrazoline Hybrid Derivatives As Potential Topoisomerase 1 Inhibitors

Topoisomerase I inhibitors: Challenges, progress and the road ahead

Topoisomerase I inhibitors: Review and update

Synthesis, cytotoxic activities and structure-activity relationships of topoisomerase I inhibitors: indolizinoquinoline-5,12-dione derivatives.

A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade

Design, synthesis and evaluation of 4-substituted anthra[2,1-c][1,2,5]thiadiazole-6,11-dione derivatives as novel non-camptothecin topoisomerase I inhibitors

Synthesis and biological evaluation of indeno[1, 2-b]indole derivatives as dual topoisomerase Ⅰ & Ⅱ inhibitors: novel multidrug resistant reversal anticancer agents

Indenoisoquinoline Derivatives As Topoisomerase I Inhibitors That Suppress Angiogenesis by Affecting the HIF Signaling Pathway.

Recent developments in the clinical activity of topoisomerase-1 inhibitors